



The Spectrum of Interstitial Lung Disease Associated
with Autoimmune Diseases: Data of a 3.6-Year
Prospective Study from a Referral Center of
Interstitial Lung Disease and Lung Transplantation †
Belén Atienza-Mateo 1,2,‡ , Sara Remuzgo-Martínez 1,‡, Víctor Manuel Mora Cuesta 1,3,
David Iturbe-Fernández 1,3, Sonia Fernández-Rozas 1,3, Diana Prieto-Peña 1,2 ,
Mónica Calderón-Goercke 1,2, Alfonso Corrales 1,2, Gerardo Blanco Rodríguez 4,
José Javier Gómez-Román 5,6 , Miguel Ángel González-Gay 1,2,6,7,§ and
José Manuel Cifrián 1,3,6,*,§
1 Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone
Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain;
mateoatienzabelen@gmail.com (B.A.-M.); sara.r.mtz@gmail.com (S.R.-M.);
victormanuel.mora@scsalud.es (V.M.M.C.); david.iturbe@scsalud.es (D.I.-F.);
soniam.fernandez@scsalud.es (S.F.-R.); diana.prieto.pena@gmail.com (D.P.-P.);
monipcg89@hotmail.com (M.C.-G.); afcorralesm@hotmail.com (A.C.);
miguelaggay@hotmail.com (M.Á.G.-G.)
2 Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain
3 Department of Pneumology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain
4 Department of Radiology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain;
gerardo.blanco@scsalud.es
5 Department of Pathology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain;
josejavier.gomez@scsalud.es
6 School of Medicine, Universidad de Cantabria, 39011 Santander, Spain
7 Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health
Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa
* Correspondence: josecifrian@gmail.com; Tel.: +34-942-202-250
† The results of this work were partially presented at the 2019 ACR Meeting in Atlanta, GA, USA (abstract no.
2155) (View Abstract and Citation Information Online-
https://acrabstracts.org/abstract/the-spectrum-of-interstitial-lung-disease-associated-with-autoimmune-
diseases-data-of-a-3-year-prospective-study-from-a-referral-center-of-lung-transplantation/).
‡ Belén Atienza-Mateo and Sara Remuzgo-Martínez shared first authorship.
§ Miguel A. González-Gay and José M. Cifrián shared senior authorship.
Received: 19 April 2020; Accepted: 22 May 2020; Published: 26 May 2020


Abstract: Interstitial lung disease (ILD) may occur in patients with a rheumatic autoimmune disease
(AD), increasing their risk of morbidity and mortality. However, little is known about the prevalence
of AD in patients diagnosed with an ILD. In this prospective study, we determined the spectrum of
ILD associated with AD (AD-ILD) among patients sent for assessment to a single clinic of ILD and
lung transplantation from a referral center between May 2016 and December 2019. ILD diagnosis
was made by pneumologists based on clinical and radiological findings and pulmonary function test
abnormalities. All patients with ILD were also assessed by experienced rheumatologists. During the
period of assessment, 338 patients were diagnosed with ILD. Among them, 32.8% fulfilled definitions
for an AD. Most cases with AD-ILD had a diagnosis of rheumatoid arthritis (27.0%), systemic sclerosis
(26.1%) or anti-synthetase syndrome (17.1%). Interestingly, 18% of the patients with AD-ILD were
diagnosed as having an interstitial pneumonia with autoimmune features. Antinuclear antibodies and
non-specific interstitial pneumonia were the most frequent positive autoantibodies and radiological
pattern found in AD-ILD patients, respectively. In conclusion, our study indicates that a high number
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of ILD patients have a related AD. Consequently, close collaboration among rheumatologists and
pneumologists is needed.
Keywords: interstitial lung disease; rheumatic autoimmune diseases; connective tissue diseases;
interstitial pneumonia with autoimmune features
1. Introduction
Interstitial lung diseases (ILDs) comprise a wide range of parenchymal lung disorders with
a known possible cause (e.g., allergens, occupational exposures, pharmacotoxicity or rheumatic
autoimmune diseases (ADs)) or with an unknown origin, also called idiopathic interstitial pneumonias
(IIPs). The latter are classified as major, rare or unclassifiable IIPs. Idiopathic pulmonary fibrosis (IPF)
is one of the major chronic fibrosing IIP [1]. An early and precise diagnosis of these ILDs is crucial since
the different pathologies that encompass ILD have different prognoses and therapeutic options [2].
ADs are a compilation of pathological entities characterized by the existence of circulating
autoantibodies that can produce systemic organ damage [3]. The group of rheumatic ADs mainly
includes connective tissue diseases (CTD), also known as collagen vascular diseases, such as rheumatoid
arthritis (RA), systemic sclerosis (SSc), systemic lupus erythematosus, primary Sjögren’s syndrome,
idiopathic inflammatory myositis (IIM) (polymyositis, dermatomyositis, anti-synthetase syndrome) and
mixed connective tissue disease. Systemic vasculitis and spondyloarthropathies are also incorporated
in the ADs spectrum [4,5]. ILD may occur in any of these ADs, especially in the context of a CTD,
and vice versa, with variable frequency and severity [6,7]. The prevalence of ILD in patients with an
established AD varies from different reports and the particular AD. In this regard, it has been reported
that SSc and IIM are associated more frequently with an ILD development (prevalence ranges from 35
to 53% for SSc and 20 to 86% for IIM). A clinically significant ILD is found in 8–15% of RA patients,
whereas subclinical ILD detected by high-resolution computed tomography (HRCT) may occur in
around 30% of RA patients [2,7–11]. However, little is known about the prevalence of AD in patients
diagnosed with an ILD, being reported that approximately 30% of them fulfill criteria of an AD [12].
In 2015, the European Respiratory Society/American Thoracic Society proposed the term of
interstitial pneumonia with autoimmune features (IPAF) to describe patients with ILD and clinical,
serological, radiographic and/or histological characteristics that suggest the presence of an underlying
AD but do not meet the criteria established for a CTD [13]. This concept is broadening thanks to the
knowledge expansion in this area, changes in CTD criteria and identification of new biomarkers [14–16].
The presence of an ILD entails an increase in the patient’s morbidity and mortality, with different
prognostic features depending on the subtype of ILD. Usually, the long-term prognosis of patients
with AD-associated ILD (AD-ILD) is less severe than that of IPF. This may be in part due to the use of
immunosuppressive therapies for the treatment of the underlying AD [7,17,18]. In addition, in some
cases, patients initially diagnosed as having IPF may become an AD-ILD, which implies different
therapeutic strategies to those of IPF [19]. Because of that, careful clinical and laboratory evaluation
is required in patients with IPF, excluding the presence of an underlying AD, even in the absence of
obvious autoimmune features. In this sense, the participation of rheumatologists becomes essential in
the multidisciplinary evaluation of ILDs [20,21].
In the present study, we aimed to determine the frequency and different types of AD-ILD among
patients with suspected ILD sent for assessment to a single clinic of ILD and lung transplantation
from a referral center. In addition, the immunological and radiological patterns were assessed in
these patients.
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2. Materials and Methods
2.1. Patients
We performed an observational prospective study of a series of consecutive patients referred to
the Marqués de Valdecilla University Hospital (Santander, Spain) between May 2016 and December
2019. All patients gave their informed consent for inclusion in the study. The study was conducted in
accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee
of clinical research of Cantabria, Spain (2016.092). A diagnosis of ILD was made by the pneumologists
based on clinical and radiological findings and pulmonary function test abnormalities following the
clinical guidelines [1,22]. A definitive histological confirmation by transbronchial biopsy, surgical lung
biopsy (including lung explants biopsy) or cryobiopsy was performed by experienced pathologists
according to the pneumologist consideration. Since collaboration with the rheumatologists was started,
we assessed not only patients sent for lung transplant evaluation but also patients with ILD to exclude
the presence of an underlying AD and/or to optimize the management of an already diagnosed
rheumatic condition. In this sense, all patients underwent an accurately anamnesis and physical
examination to perform a rheumatological disease screening. If there was certain suspicion for an
AD-ILD, autoimmune serologies were assessed.
A total of 433 patients satisfied the criteria for ILD. Those who fulfilled criteria for the
selection of lung transplant candidates, according to the Pulmonary Transplantation Council of
the International Society for Heart and Lung Transplantation [23], were included in the lung transplant
list. In this regard, by the end of the study, 133 patients had received a lung transplant. Patients with
hypersensitivity pneumonitis (n = 45), Langerhans cell histiocytosis (n = 14), sarcoidosis (n = 10),
lymphangioleiomyomatosis (n = 10), pneumoconiosis (n = 6), asbestosis (n = 3), Hermansky–Pudlak
syndrome (n = 3), drug and radiation-induced ILD (n = 3) and lipoid pneumonia (n = 1) were excluded
to have a more homogeneous group. Finally, 338 patients with ILD were assessed and distributed in
3 categories according to their diagnosis: AD-ILD, IPF and IIP-non IPF. Different rheumatic ADs were
classified according to the applicable diagnostic criteria [24–30]. IPAF was also considered as part of
the AD-ILD spectrum [13]. Figure 1 shows the workflow of the 433 patients assessed in our clinic.
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Figure 1. Flow diagram of patients’ assessment in our interstitial lung disease (ILD) and
lung transplantation clinic. The term of “lung transplant patients” stands for patients actually
transpla ted by the end of follow-up of the study. a The major alternative ILD diagnosis includes
hypersensitivity pneumonitis (n = 45), Langerhans cell histiocytosis (n = 14), sarcoido s (n = 10) and
lymphangioleiomyomatosis (n = 10).
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2.2. Methods
Demographic and clinical features were recorded in the whole group of ILD patients, including
sex, age, smoking status and pulmonary function tests (PFTs). In addition, in the AD-ILD group,
autoantibodies profile (rheumatoid factor (RF), anti-citrullinated protein antibody (ACPA), antinuclear
antibody (ANA), anti-SSa/Ro, anti-SSb/La, anti-Scl 70 and myositis-associated antibodies, among
others) and HRCT images of the chest were evaluated by experienced immunologists and radiologists,
respectively. The HRCT patterns were stratified according to the histopathologic criteria for usual
interstitial pneumonia (UIP) pattern of the Fleischner Society: UIP pattern, probable UIP pattern,
indeterminate for UIP pattern and features most consistent with an alternative diagnosis [31].
2.3. Descriptive Statistical Analysis
Results were expressed as number of individuals (n) and percentage (%) for categorical variables.
The differences in gender, smoking habit and lung transplantation between groups were analyzed
by chi-squared test. For continuous variables, Shapiro–Wilk test was performed to determine the
distribution of the data. Mean ± standard deviation or median [25th–75th interquartile range] were
used when data were normally or not normally distributed, respectively. Age and PFTs between
AD-ILD, IPF and IIP-non IPF patients were compared by Kruskal–Wallis and ANOVA test, respectively.
In addition, differences between age and PFTs were also determined between pairwise comparison by
Mann–Whitney U-test and Student’s t-test, respectively. A p-value <0.05 was considered statistically
significant. Statistical analysis was carried out with STATA statistical software 12/SE (Stata Corp.,
College Station, TX, USA).
3. Results
3.1. Characteristics and Categories of ILD Patients According to Their Diagnosis
During the period of assessment (3.6 years), a total of 338 patients (108 women/230 men) diagnosed
with ILD at the reference clinic mentioned above were included. The median age at ILD diagnosis was
59 (52–64) years (Table 1). The diagnosis of ILD was histologically confirmed in 170 (50.3%) patients.
Among the 338 ILD patients, 143 (42.3%) were diagnosed as having IPF, 111 (32.8%) fulfilled definitions
for an AD and 84 (24.9%) patients were classified as having an IIP-non IPF (49 with unclassifiable IIP,
23 with idiopathic non-specific interstitial pneumonia (NSIP), 5 with pleuroparenchymal fibroelastosis,
4 with respiratory bronchiolitis-ILD, 1 with desquamative interstitial pneumonia, 1 with idiopathic
lymphoid interstitial pneumonia, and 1 with cryptogenic organizing pneumonia). Demographic and
clinical characteristics of the ILD patients are shown in Table 1.
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n = 84 p-Value
a p-Value b p-Value c p-Value d
Sex (women/men), n (%) 108/230 (32.0/68.0) 53/58 (47.7/52.3) 24/119 (16.8/83.2) 31/53 (36.9/63.1) <0.001 <0.001 0.13 <0.001
Age at ILD diagnosis, years, median [IQR] 59 (52–64) 57 (50–63) 60 (55–64) 58 (44–66) 0.01 0.006 0.87 0.025
Smoking ever, n (%) 232 (68.6) 69 (62.2) 113 (79.0) 50 (59.5) 0.002 0.003 0.71 0.002
Pulmonary function tests
FEV1 (% predicted), mean ± SD 76.4 ± 22.6 79.2 ± 24.7 77.5 ± 20.3 70.8 ± 22.8 0.029 0.56 0.018 0.024
FVC (% predicted), mean ± SD 77.6 ± 23.0 81.8 ± 25.0 77.4 ± 19.9 72.4 ± 24.3 0.018 0.12 0.009 0.09
FEV1/FVC (% predicted), mean ± SD 78.9 ± 9.6 77.9 ± 8.7 79.0 ± 9.2 80.0 ± 11.2 0.33 0.35 0.15 0.47
DLCO (% predicted) mean ± SD 36.7 ± 15.1 38.2 ± 14.7 34.9 ± 15.4 37.9 ± 14.9 0.28 0.15 0.92 0.25
Actual lung transplant received, n (%) 82 (24.3) 18 (16.2) 45 (31.5) 19 (22.6) 0.018 0.005 0.26 0.15
AD: autoimmune diseases, DLCO: diffusing capacity of the lung for carbon monoxide, FEV1: forced expiratory volume in one second, FVC: forced vital capacity, IIP: idiopathic interstitial
pneumonia, ILD: interstitial lung disease, IPF: idiopathic pulmonary fibrosis, IQR: interquartile range, SD: standard deviation. a Comparison between AD-ILD, IPF and IIP-non IPF
patients. b Comparison between AD-ILD and IPF patients. c Comparison between AD-ILD and IIP-non IPF patients. d Comparison between IPF and IIP-non IPF patients.
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3.2. Spectrum of AD-ILD Patients
Regarding the group of the 111 AD-ILD patients, most patients had a diagnosis of RA (27.0%,
n = 30), SSc (26.1%, n = 29) or anti-synthetase syndrome (17.1%, n = 19). Interestingly, 20 patients with
AD-ILD (18.0%) were diagnosed as having an IPAF. Other ADs associated with ILD found at a lower
frequency were primary Sjögren’s syndrome (5.4%, n = 6), amyopathic dermatomyositis (1.8%, n = 2),
systemic lupus erythematosus (1.8%, n = 2), eosinophilic granulomatosis with polyangiitis (0.9%, n = 1),
microscopic polyangiitis (0.9%, n = 1) and mixed connective tissue disease (0.9%, n = 1) (Table 2).
Within the serological data available, the most frequent positive autoantibodies found in AD-ILD
patients were ANA (71.1%), myositis-associated antibodies (47.3%), ACPA (42.4%), RF (39.2%),
anti-SSa/Ro (32.1%) and anti-Scl 70 (24.6%) (Table 2). In particular, 88.9% of RA-ILD patients were ACPA
and RF positive whereas 28.6% were ANA positive. In SSc-ILD patients, the most frequent positive
autoantibody was ANA (95.7%) followed by anti-Scl 70 (60.9%). All patients with anti-synthetase
syndrome (n = 19) had positive myositis-associated antibodies, being the most frequent anti-Ro 52
(42.1%, n = 8/19), anti-Pl 7 (36.8%, n = 7/19), anti-Pl 12 (21.1%, n = 4/19) and anti-Jo 1 (21.1%, n = 4/19).
Interestingly, in IPAF patients, the most frequent positive autoantibody was ANA (84.2%), followed by
RF (25%).
Regarding the HRCT patterns, NSIP was the predominant radiological pattern found in patients
with AD-ILD (39.1%, n = 43/110), whereas UIP pattern was present in 37.3% of the patients (n = 41/110).
However, it is worth mentioning that 16% of them had a probable UIP pattern (Table 2). Specifically,
NSIP was the most frequent pattern in patients with SSc-ILD and anti-synthetase syndrome (50%
and 52.6%, respectively) whereas UIP was the main pattern in RA-ILD and IPAF patients (60% and
40%, respectively) (Table 3). Additionally, 34 (30.6%) of these 111 patients underwent a lung biopsy.
The most common histological finding was that suggestive of UIP (35.3%, n = 12/34), followed by NSIP
(17.6%, n = 6/34) and other alternative patterns (17.6%, n = 6/34). Description of histological findings
and HRCT patterns, according to each rheumatic AD is shown in Supplementary Table S1.
4. Discussion
In reference centers such as ours, patients from different parts of the country are treated for lung
processes that often require transplantation. In this regard, there is great concern among pneumologists
and rheumatologists about the need to establish early recognition and management of a related
autoimmune pathology in patients referred for an ILD. However, the confirmation of an ILD diagnosis
associated with an AD requires a highly qualified multidisciplinary team [21,32].
In this 3.6-year prospective study, we determined the frequency and the spectrum of the different
types of AD-ILD among 338 consecutive patients referred to our ILD multidisciplinary unit. As expected,
IPF was the most frequent ILD (42.3%). Interestingly, 32.8% (n = 111) of the ILD patients had an
associated AD. This relevant frequency is in accordance with a study reported by of Mittoo et al., where
34 of 114 patients with ILD (30%) had a well-defined CTD-ILD [12], thus reinforcing the importance to
identifying this group of patients. The remaining ILD patients were diagnosed as having an IIP-non
IPF (24.9%), mainly with unclassifiable IIP (14.5% of ILD patients). Similarly, it has been reported that
around 15% of ILD patients have unclassifiable IIP, being essential an appropriate management of
these patients [33].
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Table 2. Spectrum of the 111 AD-ILD patients included in the study.
Rheumatic autoimmune disease n (%)
Rheumatoid arthritis 30 (27.0)
Systemic sclerosis 29 (26.1)
Interstitial pneumonia with autoimmune features 20 (18.0)
Anti-synthetase syndrome 19 (17.1)
Others a 13 (11.8)
Autoantibody profile b n/N (%)
Rheumatoid factor 31/79 (39.2)
Anti–citrullinated protein antibody 25/59 (42.4)
Antinuclear antibody 64/90 (71.1)
Anti-SSa (Ro) 17/53 (32.1)
Anti-SSb (La) 4/50 (8.0)
Anti-Scl 70 15/61 (24.6)
Myositis-associated antibodies c 26/56 (46.4)
Others d 15/67 (22.4)
High-resolution computed tomography pattern n (%)
UIP pattern 41 (37.3)
Probable UIP pattern 16 (14.5)
Indeterminate for UIP pattern 3 (2.7)
Features most consistent with an alternative diagnosis
NSIP pattern 43 (39.1)
Non-NSIP pattern 7 (6.4)
AD: autoimmune diseases, ILD: interstitial lung disease, N: data available, NSIP: non-specific interstitial pneumonia,
UIP: usual interstitial pneumonia. a Includes primary Sjögren’s syndrome (n = 6), amyopathic dermatomyositis
(n = 2), systemic lupus erythematosus (n = 2), eosinophilic granulomatosis with polyangiitis (n = 1), microscopic
polyangiitis (n = 1) and mixed connective tissue disease (n = 1). b Patients may have more than one antibody.
c Includes anti-Ro 52 (n = 10), anti-Pl 7 (n = 7), anti-Pl 12 (n = 4), anti-Jo 1 (n = 4), anti-PML-Scl (n = 2), anti-Ku
(n = 2), anti-MDA 5 (n = 1), anti-NOR 90 (n = 1) and anti-fibrillarin (n = 1) antibodies. d Includes anti-RNP (n = 5),
anti-phospholipid (n = 4), anti-neutrophil cytoplasmic (n = 4), anti-DNA (n = 1), anti-smooth muscle (n = 1) and
anti-Smith (n = 1) antibodies.









UIP pattern 18 (60.0) 6 (21.5) 8 (40.0) 5 (26.3)
Probable UIP pattern 2 (6.7) 4 (14.3) 4 (20.0) 4 (21.1)
Indeterminate for UIP pattern 1 (3.3) 2 (7.1) - -
Features most consistent with an
alternative diagnosis
NSIP pattern 8 (26.7) 14 (50.0) 5 (25.0) 10 (52.6)
Non-NSIP pattern 1 (3.3) 2 (7.1) 3 (15.0) -
AD: autoimmune diseases, HRCT: high-resolution computed tomography, ILD: interstitial lung disease,
IPAF: interstitial pneumonia with autoimmune features, NSIP: non-specific interstitial pneumonia, RA: rheumatoid
arthritis, SSc: systemic sclerosis, UIP: usual interstitial pneumonia. Non information about HRCT pattern was
available in one patient with SSc-ILD.
According to the demographic and clinical features of our ILD patients, the median age at disease
diagnosis was significantly higher in the IPF group compared to the AD-ILD and IIP-non IPF groups.
Regarding gender, in the IPF group, the percentage of men was significantly predominant. However,
in the AD-ILD group, sex distribution tended to be more balanced. This was probably due to the
fact that ADs are usually more frequent in women [34]. More than a half of the patients in each
group had ever smoked, but the higher percentage of smokers was in the IPF group. With respect
to the PFTs, although no statistically significant differences were observed between AD-ILD and IPF
groups, volume and diffusion parameters were higher in the AD-ILD group. In addition, DLCO was
importantly reduced in the IPF group, as expected, due to the particular severity of lung involvement
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in that group. In accordance with this, the proportion of lung transplant patients was significantly
higher in the IPF group compared to the AD-ILD group.
Within the group of AD-ILD patients, the most frequent rheumatic AD seen in our clinic was RA
(27.0%), closely followed by SSc (26.1%). Although it has been reported that SSc is more frequently
associated with ILD [7,11], it should also be taken into consideration that the prevalence of RA is higher
than SSc (0.5–1% vs. 0.003–0.03% respectively [35,36]). The percentage of SSc-ILD in our center was also
considerable. This may be explained by the increased detection of lung involvement through routine
screening with pulmonary function tests in SSc patients or an early diagnosis of ILD in patients with
suspicious symptoms of SSc, such as Raynaud’s phenomenon. A substantial percentage of patients
in the group of AD-ILD met criteria for IPAF (18.0%). In keeping with this, Fernandes et al. has
recently pointed out that a substantial number of patients with ILD present autoimmune features but
do not fulfill criteria for any defined CTD [37]. It is worth mentioning that patients initially diagnosed
with IPAF can meet the definitions for a well-established AD during their follow-up. That was the
case of a woman of our series, who was diagnosed as having SSc after the performance of a nailfold
videocapillaroscopy and a new immunoblot. However, IPAF’s tendency to evolve into a definitive
CTD is controversial [38,39].
Within the serological available data in the AD-ILD patients from our series, ANA was the most
common antibody. According to other studies, the presence of ANA in a patient with ILD, in whom an
AD is suspected, has a high positive predictive value for the diagnosis of a rheumatologic condition [40].
The majority of RA-ILD patients from our series were ACPA and RF positive. These findings are in
agreement with former studies that emphasized the relevance of ACPA positivity as a risk factor for
the development of ILD in patients with RA [10,41,42]. More than a half of the patients with SSc-ILD
showed Scl 70 antibody positivity. This frequency was higher than in former reports [43–45]. Therefore,
our data support the claim that the presence of anti-Scl 70 in patients with SSc is an important reason
for monitoring lung involvement in these patients [8,46]. All patients with anti-synthetase syndrome
had positive myositis-associated antibodies, the most frequent being, in decreasing order, anti-Ro 52,
anti-Pl 7, anti-Pl 12 and anti-Jo 1. These serological data are consistent with previous reports that
showed a higher frequency of ILD in anti-Jo-1 negative anti-synthetase syndrome patients [47–49].
As previously reported, patients from our series with diagnosis of IPAF presented high positivity of
ANA antibodies [32,37].
In accordance with previous reports, HRCT images in the group of AD-ILD patients from our
series yielded a predominant NSIP pattern [1,50]. However, an UIP pattern was also common among
AD-ILD patients. This may be explained by the high number of patients with RA diagnosis in our
study. It also highlights the need of excluding an underlying AD in patients with UIP findings [51,52].
Lung histological study was performed in a few patients with AD-ILD. Consistently with Mittoo et al.,
a histology suggestive of UIP was found in a considerable number of patients, demonstrating again
that UIP does not exclude the possibility of an associated AD [12].
Our findings might be somehow limited due to the fact the autoimmune screening was addressed
to patients with certain clinical suspicion for an AD-ILD. Consequently, the number of IPAF patients
could have been underestimated. Otherwise, the major strength of this study was the prospective
data collection of a high number of ILD patients, reflecting what is happening in real clinical practice.
In addition, the prevalence of AD-ILD among patients with suspected ILD has not been widely reported
before. It would also be interesting to prospectively assess the outcomes of these AD-ILD patients in
the future, especially the predictors of response to different therapies. In this line, further studies are
needed to report the evolution of AD-ILD patients undergoing lung transplantation.
In conclusion, our study indicates that a high number of patients seen in the ILD clinics have a
related AD. Consequently, close collaboration among rheumatologists and pneumologists is needed to
make an accurate diagnosis that may facilitate immune therapy and a better patient outcome.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/6/1606/s1,
Table S1: Description of histological and radiological findings in 34 patients of the AD-ILD group.
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